A clinical trial to evaluate the efficacy of shwadanshtradi ghana vati as compare to tablet cefixime in the management of garbhini mutrakrichhra (urinary tract infection during pregnanacy)

EFFICACY OF SHWADANSHTRADI GHANA VATI AS COMPARED TO TABLET CEFIXIME IN THE MANAGEMENT OF GARBHINI MUTRAKRICCHRA (URINARY TRACT INFECTION DURING PREGNANCY) â?? RANDOMISED CONTROLLED CLINICAL TRIAL

Status

Active, not recruiting

Phases

Phase 3Phase 4

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2023/05/052987

Enrollment

Registered

2023-05-22

Start date

Unknown

Completion date

Unknown

Last updated

2023-05-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: N342- Other urethritis Health Condition 2: N390- Urinary tract infection, site notspecified

Interventions

None listed

Eligibility

Inclusion criteria

Inclusion criteria: Pregnant women (Primigravida or Multi gravida) with age of 20 to 35 years who are attending AIIA Hospital for Ante natal care with gestational age from 16 weeks to 36 weeks with signs & symptoms of Mutrakricchra (UTI during Pregnancy) - Sadah Mutrata (Burning Micturition), Saruja Mutrata (Painful Micturition), Muhur muhur mutrata (Frequency Micturition), Adho udar shola (Lower abdominal pain). • Pregnant women with asymptomatic Bacteriurea. (Patients those who are not having any signs & symptoms of UTI, but there Lab reports of Urine analysis and Urine culture are suggestive of UTI.) • Pregnant women willing for trial.

Exclusion criteria

Exclusion criteria: All non-pregnant women with UTI. • Postpartum UTI. • Pre-existing congenital renal tract anomalies. • Pregnant Women with chronic renal disorders, Polycystic kidneys, Hydronephrosis, Impaired renal function. • Pregnant women who need hospitalization for urinary problem with uterine discomfort with urine analysis and urine culture report suggestive of UTI. • Malignancy of Urinary Tract. • Immuno-compromised patients. • Pregnant women with severe anemia Hb • Pregnancy complicated with other medical disorders. • Any complication in pregnancy like Polyhydroamnios, Placental abnormalities. • Pregnancy induced hypertension. • Gestational Diabetes Mellitus. • Pregnancy with thyroid dysfunction, High Risk Pregnancy

Design outcomes

Primary

Measure	Time frame
Relief in signs and Symptoms in Garbhini MutrakricchraTimepoint: patient will be assessed on 5th, 10th day and 17th day based on sign and symptomes of mutrakricchra	—

Secondary

Measure	Time frame
To evaluate the efficacy of Shwadanshtradi ghana vati by Urine (Random & Microscopic) examination and Urine culture & sensitivity reportTimepoint: 1 to 5 days	—

Countries

India

Contacts

Public ContactJuli kotwani

all India institute of Ayurveda

tejaswinidevadhe@gmail.com7011654967

Outcome results